Literature DB >> 23997193

A UK survey of the impact of cancer on employment.

K Luker1, M Campbell, Z Amir, L Davies.   

Abstract

BACKGROUND: Improvements in cancer detection and treatment and an increase in retirement age mean more people may experience cancer during their working lives. AIMS: To examine the impact of cancer on work activities, sources of advice and support for return-to-work decisions and the role of employers in supporting employees with cancer.
METHODS: A cross-sectional survey of a randomly selected sample of people from two cancer registries was conducted in England. Eligible individuals were invited to participate via their general practitioners (April-October 2011) and completed a questionnaire online or by telephone interview. Survey weights were applied before statistical analysis, ensuring responses were representative of cancer survivors in the random sample.
RESULTS: A total of 382 people completed the survey, 27% of those invited to participate. Full-time employment fell from 53% prior to diagnosis to 33% after diagnosis, and average working hours reduced from 38 to 32h per week. Only 48% discussed employment issues with their oncology treatment team, and this was associated with more hours worked (36.7 versus 29.4h). Seventy-six per cent of employers were perceived to have been very supportive and 56% receptive to a phased return-to-work.
CONCLUSIONS: This is one of the largest UK registry-based surveys on this subject. Following treatment for cancer, there were significant falls in full-time working and hours worked. Just under half the sample discussed employment issues with their treatment team, and these participants worked significantly more hours. This indicates scope for improvement such as encouraging health professionals to raise work-related issues within time-limited consultations.

Entities:  

Keywords:  Cancer survivor; employment; return-to-work; vocational services; working hours.

Mesh:

Year:  2013        PMID: 23997193     DOI: 10.1093/occmed/kqt104

Source DB:  PubMed          Journal:  Occup Med (Lond)        ISSN: 0962-7480            Impact factor:   1.611


  7 in total

1.  Predictors of return to work in cancer survivors in the Royal Air Force.

Authors:  Kenneth Murray; Kin Bong Hubert Lam; David C McLoughlin; Steven S Sadhra
Journal:  J Occup Rehabil       Date:  2015-03

2.  Work Transitions in Breast Cancer Survivors and Effects on Quality of Life.

Authors:  Rola Hamood; Hatem Hamood; Ilya Merhasin; Lital Keinan-Boker
Journal:  J Occup Rehabil       Date:  2019-06

3.  Return to work in European Cancer survivors: a systematic review.

Authors:  Sara Paltrinieri; Stefania Fugazzaro; Lucia Bertozzi; Maria Chiara Bassi; Martina Pellegrini; Massimo Vicentini; Elisa Mazzini; Stefania Costi
Journal:  Support Care Cancer       Date:  2018-05-29       Impact factor: 3.603

4.  Comparing men's and women's experiences of work after cancer: a photovoice study.

Authors:  T L Morrison; R L Thomas
Journal:  Support Care Cancer       Date:  2015-03-05       Impact factor: 3.603

5.  Patient and provider communication about employment following a cancer diagnosis.

Authors:  Janet S de Moor; Kisha Coa; Erin E Kent; Carmen Moten; Sarah Kobrin; Cheryl Altice; K Robin Yabroff
Journal:  J Cancer Surviv       Date:  2018-10-03       Impact factor: 4.442

6.  Labor-force participation and working patterns among women and men who have survived cancer: A descriptive 9-year longitudinal cohort study.

Authors:  Birgit Brusletto; Roy A Nielsen; Harald Engan; Line Oldervoll; Camilla M Ihlebæk; Nina Helen Mjøsund; Steffen Torp
Journal:  Scand J Public Health       Date:  2020-09-04       Impact factor: 3.021

7.  Understanding the financial and psychological impact of employment disruption among caregivers of pediatric HSCT recipients: a mixed methods analysis.

Authors:  Caitlin B Biddell; Kimberly A Kasow; Mary K Killela; Kristin M Page; Stephanie B Wheeler; Sarah W Drier; Matthew S Kelly; Joanna M Robles; Lisa P Spees
Journal:  Support Care Cancer       Date:  2022-02-07       Impact factor: 3.359

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.